EDIT Editas Medicine, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR에서 보기 ↗ 종가 10월 2, 2026 10-K/10-Q 8월 5, 2026
$2.62
· 52주 범위 %
· 저점 이상
· 고점까지
$1.6752주 저점
$4.5452주 고점
시가총액 (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
매출 (TTM)
$47M
내 배지
52주 범위
$2–$5
애널리스트 평점
BUY
목표 주가
$6
P/E
-4.0
ROE
-118.8%
순이익률
-157.3%
배지 스트립이 비어 있습니다. 이 페이지의 아무 지표나 고정하세요.
EDIT 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$2.62
시가총액 (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
매출 (TTM)
$47M
ROE (TTM)
-118.8%
부채/자본 (MRQ)
0.5
52주 범위
$2–$5
EDIT 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
범위
막대
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
Editas Medicine, Inc. - Common Stock 정보 위키백과 회사 개요
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
섹터Healthcare
산업Biotechnology
직원87
국가US
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출$41M2016-12-31 → 2025-12-31
EPS$-1.802019-12-31 → 2025-12-31
잉여현금흐름$-166M2016-12-31 → 2025-12-31
순이익률-157.3%2018-12-31 → 2025-12-31
가치 평가 및 비율
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | EDIT | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E (TTM) | -4.05년 평균 ≈-3.7 | ≈-3.7 | · | · | |
| P/S (TTM) | 5.55년 평균 ≈24.2 | ≈24.2 | 11.6 | 저평가 | |
| P/B (MRQ) | 2.45년 평균 ≈3.1 | ≈3.1 | 2.2 | 고평가 | |
| EV / EBITDA | -1.1 | · | · | · | |
| 주가 / FCF (TTM) | -2.15년 평균 ≈-4.3 | ≈-4.3 | · | · | |
| 주가 / 현금 흐름 (TTM) | -2.15년 평균 ≈-4.5 | ≈-4.5 | · | · | |
| EV / 매출 (TTM) | 2.1 | · | · | · | |
| EV / FCF (TTM) | -0.8 | · | · | · | |
| Price / Tangible Book (주가 / 유형 장부 가치) | 9.45년 평균 ≈3.1 | ≈3.1 | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | EDIT | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 영업이익률 (TTM) | -161.4%5년 평균 ≈-658.2% | ≈-658.2% | -334.4% | 최상위권 | |
| EBITDA Margin (EBITDA 마진) | -394.9%5년 평균 ≈-658.2% | ≈-658.2% | -334.4% | 최상위권 | |
| 순이익률 (TTM) | -157.3%5년 평균 ≈-639.3% | ≈-639.3% | -300.0% | 최상위권 | |
| ROA (TTM) | -33.0%5년 평균 ≈-43.0% | ≈-43.0% | -47.0% | 약함 | |
| ROE (TTM) | -118.8%5년 평균 ≈-195.1% | ≈-195.1% | -63.2% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | EDIT | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 (MRQ) | 0.5 | · | 0.0 | 높은 부채 | |
| 유동비율 (MRQ) | 3.25년 평균 ≈5.9 | ≈5.9 | 5.6 | 낮은 유동성 | |
| 당좌 비율 (MRQ) | 3.15년 평균 ≈5.8 | ≈5.8 | 4.2 | 낮은 유동성 | |
| 장기 부채 / 자기 자본 (MRQ) | 0.5 | · | · | · |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | EDIT | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | 25.4%5년 평균 ≈33.7% | ≈33.7% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | 27.2%5년 평균 ≈10.1% | ≈10.1% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | -14.9% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | EDIT | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 0.25년 평균 ≈0.1 | ≈0.1 | 0.1 | 최상위권 | |
| Receivables Turnover (매출 채권 회전율) | 2.65년 평균 ≈6.1 | ≈6.1 | · | · | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$465.7K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
2.8%
다음 실적
11월 09, 2026
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 8월 10, 2026 | $-0.15 | $-0.28 | 45.5% |
| 2026년 3월 31일 | 5월 11, 2026 | $-0.26 | $-0.27 | 3.3% |
| 2025년 12월 31일 | $-0.06 | $-0.26 | 77.2% | |
| 2025년 9월 30일 | $-0.28 | $-0.30 | 7.3% | |
| 2025년 6월 30일 | $-0.63 | $-0.38 | -63.8% | |
| 2025년 3월 31일 | $-0.92 | $-0.60 | -53.1% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $1.62 | $4.27 | $5.24 | $8.09 | $6.29 | $4.83 | $4.84 | $4.68 | $3.76 | |
| Revenue / Share | $0.46 | $0.39 | $1.03 | $0.29 | $0.38 | · | · | · | · | · | |
| Cash Flow / Share | $-1.86 | $-2.55 | $-1.74 | $-2.58 | $-2.42 | · | · | · | · | · | |
| Cash / Share | $1.50 | $1.59 | $1.51 | $2.06 | $2.97 | $2.23 | $4.38 | $2.76 | $3.29 | $5.17 | |
| EPS (TTM) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
손익계산서
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $42.0K | $6M | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $41M | $44M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $16M | $17M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $58M | $61M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-58M | $-54M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $1.0K | $235.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-56M | $-53M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | $-58M | $-54M |
대차대조표
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $211M | $169M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | $209M | $283M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | $120.0K | $713.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | $7M | $8M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | $427M | $461M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | $15M | $16M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | $36M | $35M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | $20M | $19M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | $8M | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | $7M | $6M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | $19M | $20M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | $42M | $36M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | $9M | $10M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | $116M | $115M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | $-1.02B | $-962M | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | $-4M | $-3M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $415M | $465M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | 68,761,729 | 68,718,434 |
현금 흐름
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $6M | $7M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-48M | $-38M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $614.0K | $632.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $89M | $-4M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $80.0K | $367.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $41M | $-41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
수익성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | -132681.0% | -840.2% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | -8.9% | -8.0% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | -11.1% | -9.9% |
유동성 및 지급능력
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | 10.1 | 12.7 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | 9.9 | 12.4 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
효율성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | 0.2 | 12.2 |
주당
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $0.04 | · | $0.14 | $0.22 | $0.75 | · | $2.13 | $2.81 | $3.58 | · | $4.41 | $4.90 | $4.60 | $6.03 | $6.77 | |
| Revenue / Share | $0.10 | $0.03 | · | $0.08 | $0.04 | $0.06 | · | $0.00 | $0.01 | $0.01 | · | $0.07 | $0.04 | $0.14 | $0.00 | $0.09 | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $-0.58 | · | · | · | $-0.61 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.86 | $1.26 | · | $1.78 | $1.59 | $1.66 | · | $1.16 | $0.78 | $0.84 | · | $1.01 | $2.71 | $1.87 | $3.06 | $2.47 | |
| EPS (TTM) | $-0.66 | $-1.14 | · | $-2.38 | $-2.85 | $-3.04 | · | $-2.53 | $-2.33 | $-2.07 | · | $-2.70 | $-2.96 | $-3.18 | $-2.94 | $-2.70 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $47M | $39M | · | $46M | $39M | $36M | · | $62M | $67M | $69M | · | $25M | $19M | $23M | $26M | $32M | |
| Net Income TTM | $-74M | $-109M | · | $-200M | $-237M | $-251M | · | $-211M | $-193M | $-166M | · | $-195M | $-206M | $-219M | $-201M | $-184M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | $842M | $813M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.9 | -2.2 | · | -1.5 | -0.8 | -0.4 | · | -1.3 | -2.0 | -3.6 | · | -2.9 | -2.8 | -2.3 | -4.2 | -4.4 | |
| P/S | 6.7 | 6.2 | · | 7.0 | 4.9 | 2.7 | · | 4.6 | 5.7 | 8.8 | · | 25.9 | 34.8 | 21.9 | 32.8 | 25.6 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| EV / Revenue | 3.4 | 4.5 | · | 4.7 | 1.8 | -1.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -20.4% | -46.2% | · | -68.6% | -129.6% | -262.1% | · | -74.2% | -49.9% | -27.9% | · | -34.6% | -36.0% | -43.9% | -24.0% | -22.8% |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 매출 | $41M | $32M | $78M | $20M | $26M |
| 영업이익률 % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| 순이익 | $-160M | $-237M | $-153M | $-220M | $-193M |
| 희석 EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 2.1 | 0.4 | · | · | · |
| 유동비율 | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| 당좌 비율 | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-166M | $-219M | $-137M | $-181M | $-172M |
기관 투자자 (13F) 236개의 제출자 · $406.3M 전체 · 기준일 2026년 9월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
보유자
236
보유 가치
$406.3M
신규 포지션
38
청산 포지션
23
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 38 (-7 이전 분기 대비) | 23 (-3 이전 분기 대비) | 80 (+22 이전 분기 대비) | 42 (-8 이전 분기 대비) | +68.9M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36,000,000 | 11,111,111 | 8.86% | 주식 |
| BlackRock, Inc. | $34,311,568 | 10,589,990 | 8.44% | 주식 |
| RA CAPITAL MANAGEMENT, L.P. | $28,800,360 | 8,889,000 | 7.09% | 주식 |
| Commodore Capital LP | $28,800,360 | 8,889,000 | 7.09% | 주식 |
| ADAR1 Capital Management, LLC | $28,800,360 | 8,889,000 | 7.09% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $19,897,929 | 6,141,336 | 4.90% | 주식 |
| Paradigm Biocapital Advisors LP | $18,100,665 | 5,586,625 | 4.45% | 주식 |
| VANGUARD GROUP INC | $16,826,539 | 8,208,068 | 4.14% | 주식 |
| Opaleye Management Inc. | $12,512,653 | 3,861,930 | 3.08% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11,658,618 | 3,598,339 | 2.87% | 주식 |
| Woodline Partners LP | $11,519,810 | 3,555,497 | 2.84% | 주식 |
| Vivo Capital, LLC | $11,519,010 | 3,555,250 | 2.83% | 주식 |
| GordonMD Global Investments LP | $10,131,480 | 3,127,000 | 2.49% | 주식 |
| GOLDMAN SACHS GROUP INC | $8,469,476 | 2,614,036 | 2.08% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $8,325,643 | 2,569,072 | 2.05% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $7,999,298 | 2,468,919 | 1.97% | 주식 |
| Logos Global Management LP | $7,199,280 | 2,222,000 | 1.77% | 주식 |
| STATE STREET CORP | $7,101,442 | 2,191,803 | 1.75% | 주식 |
| MARSHALL WACE, LLP | $6,600,808 | 2,037,287 | 1.62% | 주식 |
| D. E. Shaw & Co., Inc. | $6,159,246 | 1,901,002 | 1.52% | 주식 |
| JPMORGAN CHASE & CO | $5,959,980 | 1,862,494 | 1.47% | 주식 |
| AQR CAPITAL MANAGEMENT LLC | $5,094,065 | 1,572,242 | 1.25% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $4,318,842 | 1,332,976 | 1.06% | 주식 |
| Seven Fleet Capital Management LP | $4,310,820 | 1,330,500 | 1.06% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $4,273,389 | 1,318,947 | 1.05% | 주식 |
| KENNEDY CAPITAL MANAGEMENT LLC | $3,344,111 | 1,032,133 | 0.82% | 주식 |
| MACKENZIE FINANCIAL CORP | $2,844,856 | 878,042 | 0.70% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,812,424 | 868,032 | 0.69% | 주식 |
| Nantahala Capital Management, LLC | $2,762,748 | 852,700 | 0.68% | 주식 |
| NORTHERN TRUST CORP | $2,655,806 | 819,693 | 0.65% | 주식 |
| TWO SIGMA ADVISERS, LP | $2,509,405 | 1,224,100 | 0.62% | 주식 |
| UBS Group AG | $2,432,472 | 750,763 | 0.60% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $2,407,158 | 742,950 | 0.59% | 주식 |
| Nuveen, LLC | $1,688,730 | 521,213 | 0.42% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $1,616,750 | 498,997 | 0.40% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $1,545,801 | 477,099 | 0.38% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,521,180 | 469,500 | 0.37% | 콜 옵션 |
| Eversept Partners, LP | $1,486,541 | 458,809 | 0.37% | 주식 |
| Casdin Capital, LLC | $1,441,800 | 445,000 | 0.35% | 주식 |
| PEAK6 LLC | $1,346,029 | 415,441 | 0.33% | 주식 |
| DIADEMA PARTNERS LP | $1,296,000 | 400,000 | 0.32% | 콜 옵션 |
| MORGAN STANLEY | $1,108,616 | 342,165 | 0.27% | 주식 |
| BIT Capital GmbH | $1,056,240 | 326,000 | 0.26% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,002,440 | 309,395 | 0.25% | 주식 |
| Cubist Systematic Strategies, LLC | $994,094 | 286,482 | 0.24% | 주식 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878,642 | 271,186 | 0.22% | 주식 |
| Bank of New York Mellon Corp | $850,907 | 262,625 | 0.21% | 주식 |
| BANK OF AMERICA CORP /DE/ | $751,119 | 231,827 | 0.18% | 주식 |
| LPL Financial LLC | $748,813 | 231,115 | 0.18% | 주식 |
| Erste Asset Management GmbH | $736,000 | 230,000 | 0.18% | 주식 |
행동주의자 및 5% 이상 소유자 1 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 제출 서류 | 2017년 9월 18일 | · | 최초 제출 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 35 명의 내부자 · 17 임원 · 17 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 2026년 9월 3일 S | 243,189 | 0 | 4 | $-80,045 |
| MULLEN JAMES C | CEO | 2022년 4월 14일 A | 75,898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 2021년 2월 9일 S | 43,760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 2019년 1월 8일 S | 1,204,966 | 0 | 0 | $0 |
| Amy Parison | SVP, Chief Financial Officer | 2026년 9월 3일 S | 13,839 | 0 | 5 | $-6,327 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 2025년 3월 8일 A | 112,720 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 2023년 5월 11일 S | 106,610 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 2019년 2월 4일 M | 0 | 0 | 0 | $0 |
| Daniel Scott Ory | EVP, Chief Medical Officer | 2026년 9월 8일 A | · | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 2026년 9월 3일 S | 61,660 | 0 | 5 | $-20,333 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 2024년 12월 3일 S | 133,354 | 0 | 0 | $0 |
| Bruce Eaton | EVP, CBO AND CTO | 2023년 12월 5일 S | 74,791 | 0 | 0 | $0 |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER | 2023년 2월 13일 S | 65,559 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 2021년 12월 22일 A | 22,675 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 2019년 10월 28일 A | 25,000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 2019년 3월 18일 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 2018년 2월 7일 A | 4,000 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | 이사 | 2026년 8월 6일 A | · | 0 | 0 | $0 |
| Elliott M. Levy | 이사 | 2026년 6월 17일 A | · | 0 | 0 | $0 |
| David Scadden | 이사 | 2026년 6월 17일 A | · | 0 | 0 | $0 |
| Bernadette Connaughton | 이사 | 2026년 6월 17일 A | · | 0 | 0 | $0 |
| Jessica Hopfield | 이사 | 2026년 6월 17일 A | 67,700 | 0 | 0 | $0 |
| Andrew Hirsch | 이사 | 2026년 6월 17일 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | 이사 | 2024년 5월 30일 A | · | 0 | 0 | $0 |
| Emma Reeve | 이사 | 2024년 5월 30일 A | · | 0 | 0 | $0 |
| Akshay Vaishnaw | 이사 | 2024년 5월 30일 A | · | 0 | 0 | $0 |
| Boris Nikolic | 이사 | 2018년 6월 15일 A | 35,000 | 0 | 0 | $0 |
| Douglas G. Cole | 이사 | 2017년 8월 17일 J | 3,171 | 0 | 0 | $0 |
| Kevin Bitterman | 이사 | 2017년 6월 15일 A | 2,797,144 | 0 | 0 | $0 |
| Alexis Borisy | 이사 | 2017년 6월 15일 A | 0 | 0 | 0 | $0 |
| John Mendlein | 이사 | 2017년 6월 15일 A | · | 0 | 0 | $0 |
| Kevin P Starr | 10% 소유주 | 2016년 9월 6일 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10% 소유주 | 2016년 2월 8일 C | 2,649,572 | 0 | 0 | $0 |
| Charles Albright | · | 2020년 12월 15일 M | 24,907 | 0 | 0 | $0 |
| Alexandra Glucksmann | · | 2017년 3월 15일 M | 117,788 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 17 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 39,171 SH | 2026년 10월 2일 | 일간 |
| IWC · iShares Trust | 0.06% | 339,728 SH | 2026년 9월 11일 | 일간 |
| IBB · iShares Trust | 0.03% | 1,101,092 SH | 2026년 9월 11일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 11,076 SH | 2026년 10월 1일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 96,927 SH | 2026년 8월 19일 | 일간 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 170,052 SH | 2026년 10월 2일 | 일간 |
| IWO · iShares Trust | 0.02% | 844,017 SH | 2026년 9월 11일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 575,834 SH | 2026년 8월 19일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.01% | 461,967 SH | 2026년 8월 19일 | 일간 |
| IWM · iShares Trust | 0.01% | 2,588,297 SH | 2026년 9월 11일 | 일간 |
| RSSL · Global X Funds | 0.01% | 47,823 NS | 2026년 7월 31일 | N-PORT |
| IWV · iShares Trust | 0.00% | 19,230 SH | 2026년 9월 11일 | 일간 |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1,100,306 SH | 2026년 8월 19일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 4,890,144 SH | 2026년 8월 19일 | 일간 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 9,046 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,608 SH | 2026년 8월 19일 | 일간 |
| IWN · iShares Trust | · | 120,579 SH | 2026년 9월 11일 | 일간 |
EDIT 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
평점 · 18 명의 애널리스트
매수
중앙값 목표
$5.00
+90.8%
5 27.8%
적극 매수
7 38.9%
매수
4 22.2%
보유
2 11.1%
매도
0 0.0%
적극 매도
12개월 목표 주가
10 명의 애널리스트 · 2026-10-04평균 목표 $5.90 +125.2%
지금
현재가 $2.62
저가$1.00
평균$5.90
고가$15.00
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| EIKN | · | · | · | · | · | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
출처: SEC 10-Q 제출 8월 5, 2026